The market already expected a positive Voyage readout, but not necessarily this magnitude. Voyage was fully enrolled and its topline data had been targeted for early third-quarter 2026, so the event itself was anticipated rather than a surprise. No reliable published numeric consensus for the HAM-A treatment effect was available; the cleanest benchmark is therefore the study’s prespecified success bar and Definium’s prior Phase 2b result.
| Metric | DT120 ODT | Placebo | Difference / result |
|---|---|---|---|
| HAM-A change at Week 12 | -11.6 | -6.2 | -5.4 points, p<0.0001; Cohen’s d=0.81 (Primary endpoint: HAM-A change from baseline to Week 12) |
| HAM-A improvement at Week 1 | — | — | 7.7-point placebo-adjusted improvement, p<0.0001 (Primary endpoint: HAM-A change from baseline to Week 12) |
| CGI-S improvement at Day 2 | — | — | 0.8-point placebo-adjusted improvement, p<0.0001 (Key secondary endpoint: CGI-S change) |
| HAM-A response at Week 12 | 43% | 16% | Odds ratio 3.5 (Response and remission rates) |
| HAM-A remission at Week 12 | 14% | 4% | Odds ratio 3.9 (Response and remission rates) |
| Participants completing Part A | 90% | 88% | — (Participant disposition) |
| Participants clearing EoSC by hour 8 | 92% | — | Average clearance time 6.4 hours; median 6.1 hours (Dosing session duration) |
The efficacy result is clearly above a binary “trial succeeded” outcome. DT120 met the primary endpoint and all hierarchically controlled key secondary endpoints, with effects appearing by Day 2 and persisting through Week 12. The 0.81 effect size is also consistent with the company’s prior Phase 2b GAD result of 0.83, reducing—but not eliminating—the risk that the earlier signal was a one-study outlier (Primary endpoint: HAM-A change from baseline to Week 12; Key secondary endpoints; Continuing to build potentially practice-changing evidence).
The practical-use profile is better than the psychedelic headline suggests. The treatment produced frequent dosing-day effects—99% reported a treatment-emergent adverse event versus 69% on placebo, including illusions, nausea, euphoric mood, disorientation and dizziness—but events were reported as mild or moderate, with no discontinuations or deaths in the DT120 arm. The 6.4-hour average session and 92% clearance by hour 8 provide an important operational datapoint for supervised administration, though this remains a clinic burden rather than an at-home treatment model (Adverse events were mild-to-moderate; Dosing session duration).
The main remaining gap is confirmation, not initial efficacy. Voyage was a 214-patient, single-dose, 100-microgram study with a 12-week blinded period; longer-term retreatment evidence is interim and open-label, so it cannot carry the same evidentiary weight as the randomized result. Panorama, which adds a 50-microgram control arm intended to address functional unblinding, remains the next pivotal test. Net: this is a meaningful positive update versus a market that already expected success, because the effect size, durability and session-time data strengthen the case for DT120—but the full GAD package still depends on Panorama (Voyage study design; Panorama description; Part B disposition; Compelling evidence across three late-stage trials).
Read the original 8-K on SEC EDGAR ↗